Group 1 - Daqian Ecological announced the resignation of Chairman Zhang Yuan due to personal reasons, affecting his roles in the board and strategic committee [1] - Daqian Ecological, established in October 1988, focuses on urban renewal, rural revitalization, and ecological restoration [1] Group 2 - Haili Biological plans to use up to 500 million yuan of idle funds to invest in financial products issued by banks, brokers, trusts, and fund companies [1] - Haili Biological, founded in July 1981, specializes in in vitro diagnostic reagents and oral tissue repair and regeneration materials [1] Group 3 - Xianglou New Materials' application for a private placement of shares has been accepted by the Shenzhen Stock Exchange [2] - Xianglou New Materials, established in December 2005, is engaged in the research, production, and sales of customized precision stamping new materials [3] Group 4 - Zhuochuang Information has submitted an application for H-share listing to the Hong Kong Stock Exchange [4] - Zhuochuang Information, founded in April 2004, provides market data monitoring, trading price evaluation, industry data analysis, and research [4] Group 5 - Zhongwei Company plans to reduce its shareholding by up to 626,150 shares, representing 1% of the total share capital [5] - Zhongwei Company, established in May 2004, focuses on the research, production, and sales of high-end semiconductor equipment and related products [5] Group 6 - Jiarong Technology intends to raise up to 1 billion yuan through a private placement to acquire 100% of Hangzhou Lanran [6] - Jiarong Technology, founded in February 2005, specializes in membrane separation equipment and high-performance membrane components [6] Group 7 - Dameng Data's director and general manager Pi Yu has had his detention lifted by the local supervisory committee [7] - Dameng Data, established in November 2000, provides various database software, cloud computing, big data products, and related technical services [7] Group 8 - Huayang Co. has launched a 200-ton annual production project for high-performance carbon fiber [8] - Huayang Co., founded in December 1999, is involved in coal production, power generation, and renewable energy technologies [8] Group 9 - Saintno Biological's executives plan to collectively reduce their holdings by up to 37,600 shares, which is 0.024% of the total share capital [9] - Saintno Biological, established in July 2001, focuses on the research, production, and sales of peptide raw materials and formulations [9] Group 10 - *ST Dongyi is in the process of signing a comprehensive technical service agreement worth 635 million yuan [10] - *ST Dongyi, founded in November 1996, provides comprehensive home decoration services [11] Group 11 - Jiangxi Copper is attempting to acquire all shares of London-listed SolGold, with a recent offer of 26 pence per share [12] - Jiangxi Copper, established in January 1997, specializes in copper and gold mining, smelting, and processing [12] Group 12 - China Shenhua's subsidiary has successfully completed a 168-hour trial run of its power generation unit [13] - China Shenhua, founded in November 2004, is involved in coal and electricity production and sales [13] Group 13 - Baile Tianheng's subsidiary has received a milestone payment of 250 million USD from BMS [14] - Baile Tianheng, established in August 2006, focuses on innovative biopharmaceuticals and chemical preparations [14] Group 14 - Yulide's directors plan to reduce their holdings by up to 35,000 shares, representing 0.0313% of the total share capital [15] - Yulide, founded in December 2003, specializes in the research, production, and sales of testing and measuring instruments [15] Group 15 - Aters plans to establish joint ventures with its controlling shareholder to adjust its U.S. market operations [15] - Aters, established in April 2006, focuses on lithium-ion battery separator products and sterile packaging [15] Group 16 - Enjie Co. is planning to acquire 100% of Zhongke Hualian's shares, leading to a stock suspension [16] - Enjie Co., founded in April 2006, specializes in lithium-ion battery separator products and sterile packaging [16] Group 17 - ST Tianrui's controlling shareholder is planning a change in company control, resulting in a stock suspension [16] - ST Tianrui, established in July 2006, focuses on analytical testing instruments and environmental governance [17]

Group 1 - Beijing Junzheng adjusted management expenses by 11.44 million yuan, increasing net profit by the same amount [1] - Ningbo Energy's subsidiary plans to publicly transfer 15% equity of Lingfeng Energy at a base price of 16.06 million yuan [1] - Dongjiang Environmental's subsidiary was fined 2.02 million yuan for tax evasion [1][2] Group 2 - AVIC's subsidiary Harbin Aircraft Industry Group plans to absorb and merge with Harbin Hafei Aviation, increasing registered capital to 3.038 billion yuan [3] - Dongfang Ocean's shareholder plans to reduce holdings by up to 3% of total shares [4] - Xinghui Entertainment's controlling shareholder plans to reduce holdings by up to 2.9% of total shares [6] Group 3 - Kaineng Health plans to acquire 100% equity of four subsidiaries for 204 million yuan [8] - Suoao Sensor's controlling shareholder changed to Zhongchuang Innovation [9] - Shanghai Port Bay reported that its commercial aerospace and perovskite solar business accounts for less than 1% of revenue [10] Group 4 - Zhonghuan Environmental's specific shareholder plans to reduce holdings by up to 2.37% of total shares [11] - Xinlaifu's asset management plan intends to reduce 874,300 shares [12] - Guangdian Measurement plans to invest 800 million yuan to build a testing base [13] Group 5 - Modern Investment plans to invest 1.04 billion yuan to establish a smart logistics company [14] - Gaole Co.'s major shareholder is planning a control change, leading to stock suspension [16] - Weiling Co.'s major shareholder is planning a control change, leading to stock suspension [18] Group 6 - Igor plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [20] - Huanrui Century's shareholder sold 7.26 million shares due to judicial enforcement [21] - Jinhua Co.'s controlling shareholder plans to acquire 5.77% of company shares at 9.15 yuan per share [22] Group 7 - Wireless Media's four shareholders plan to reduce holdings by up to 4.7% of total shares [24] - CATL's shareholder completed the transfer of 10% of shares for approximately 17.16 billion yuan [26] - *ST Lian Stone entered the restructuring phase, with potential downward adjustment of stock price [28]

Core Viewpoint - The stock price of Pulaike has experienced fluctuations, with a recent decline of 2.03% and a year-to-date increase of 11.28% [1][2]. Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [2]. - The revenue composition includes: poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2]. Financial Performance - For the period from January to September 2025, Pulaike achieved operating revenue of 823 million yuan, representing a year-on-year growth of 8.04%. The net profit attributable to the parent company was 157 million yuan, reflecting a significant increase of 47.86% [2]. - Cumulative cash dividends since the A-share listing amount to 1.125 billion yuan, with 568 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders is 16,700, a decrease of 7.26% from the previous period. The average circulating shares per person increased by 7.83% to 20,739 shares [2]. - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF ranks sixth with 5.4716 million shares, an increase of 2.0217 million shares from the previous period. Hong Kong Central Clearing Limited is the eighth largest shareholder with 3.832 million shares, marking a new entry [3].

Company Overview - KQ Bio, established on January 11, 2001, and listed on September 22, 2020, is located in Wuhan, Hubei Province. The company specializes in the research, production, and sales of veterinary biological products and animal epidemic prevention technology services [1][2]. - The main business revenue composition includes 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1]. Financial Performance - For the period from January to September 2025, KQ Bio achieved a revenue of 738 million yuan, representing a year-on-year growth of 10.87%. The net profit attributable to the parent company was 338 million yuan, showing a year-on-year increase of 29.62% [2]. - Cumulative cash dividends since the A-share listing amount to 711 million yuan, with 488 million yuan distributed over the past three years [3]. Stock Performance - As of November 17, KQ Bio's stock price was 16.24 yuan per share, with a market capitalization of 7.57 billion yuan. The stock has increased by 17.15% year-to-date but has seen a decline of 0.43% over the last five trading days, 6.13% over the last 20 days, and 5.80% over the last 60 days [1]. - The number of shareholders as of September 30 was 9,713, an increase of 2.41% from the previous period, while the average circulating shares per person decreased by 2.36% to 47,990 shares [2]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 5.5731 million shares, an increase of 3.2155 million shares from the previous period [3].

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant price movements, with a year-to-date increase of 58.86% and a recent trading volume indicating active market participation [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average number of tradable shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional holdings include the Guotai Zhongzheng Livestock Breeding ETF, which is the fourth-largest shareholder with 25.0398 million shares, an increase of 9.0897 million shares from the previous period [3].

Core Viewpoint - The stock of Wuhan Kewen Biological Technology Co., Ltd. (回盛生物) has experienced fluctuations, with a year-to-date increase of 120.22% and recent trading activity indicating a slight decline. The company operates in the veterinary pharmaceuticals sector, focusing on the research, production, and sales of veterinary drugs and feed additives [1][2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 1.26 billion yuan, representing a year-on-year growth of 58.92%. The net profit attributable to shareholders reached 188 million yuan, showing a significant increase of 494.28% compared to the previous year [2]. - Cumulatively, since its A-share listing, the company has distributed a total of 236 million yuan in dividends, with 135 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 12, the stock price was 21.70 yuan per share, with a market capitalization of 4.39 billion yuan. The stock has seen a trading volume of 72.95 million yuan and a turnover rate of 1.65% [1]. - The company has appeared on the "龙虎榜" (a stock trading list) seven times this year, with the most recent appearance on April 9, where it recorded a net buy of -65.95 million yuan [1]. Shareholder Information - As of September 30, the number of shareholders stood at 21,200, a decrease of 10.03% from the previous period. The average number of circulating shares per shareholder increased by 11.15% to 9,566 shares [2].

Core Viewpoint - Zhongmu Co., Ltd. has shown a positive stock performance with an 18.29% increase year-to-date and a significant rise in net profit for the first nine months of 2025, indicating strong operational growth in the animal health sector [1][2]. Financial Performance - As of September 30, 2025, Zhongmu Co., Ltd. achieved a revenue of 4.442 billion yuan, representing a year-on-year growth of 6.32% [2]. - The net profit attributable to shareholders reached 225 million yuan, marking a substantial increase of 175.49% compared to the previous year [2]. Stock Market Activity - On November 10, 2025, Zhongmu's stock price rose by 2.06% to 7.91 yuan per share, with a trading volume of 71.25 million yuan and a turnover rate of 0.89% [1]. - The company has a total market capitalization of 8.077 billion yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.45% to 36,900, while the average number of circulating shares per person increased by 6.90% to 27,706 shares [2][3]. - The top ten circulating shareholders include significant institutional investors, with notable changes in holdings among major ETFs [3]. Business Overview - Zhongmu Co., Ltd. specializes in animal health products, including vaccines, diagnostic liquids, and veterinary drugs, with a revenue composition of 35.78% from chemical drugs, 27.87% from trade, 19.21% from feed, and 16.10% from biological products [1]. - The company is categorized under the agricultural and animal health sectors, with involvement in various concepts such as small-cap stocks and rural revitalization [1].

Core Viewpoint - The stock price of Reap Bio fell by 2.09% on November 3, with a trading volume of 140 million yuan and a market capitalization of 9.806 billion yuan [1] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone. The company specializes in the research, production, and sales of veterinary biological products, chemical drugs, biological agents, traditional veterinary medicine, natural plant medicines, premixed feeds, feed additives, and veterinary raw materials [2] - The main business revenue composition is 77.95% from animal protection and 22.05% from the pet supply chain [2] - As of October 20, 2023, the number of shareholders is 25,000, with an average of 13,398 circulating shares per person [2] Financial Performance - For the period from January to September 2025, Reap Bio achieved a revenue of 2.544 billion yuan, representing a year-on-year growth of 45.66%. The net profit attributable to the parent company was 362 million yuan, with a year-on-year increase of 48.04% [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3] Shareholding Structure - As of September 30, 2025, the sixth largest circulating shareholder is the Guotai Zhongzheng Livestock Breeding ETF, holding 6.3383 million shares, an increase of 2.3571 million shares from the previous period. The Hong Kong Central Clearing Limited is the tenth largest shareholder, holding 3.6017 million shares, a decrease of 2.9711 million shares from the previous period [3]

Group 1 - Jinpan Technology reported a net profit of 486 million yuan for the first three quarters, a year-on-year increase of 20.27%, with total revenue of 5.194 billion yuan, up 8.25% [1] - Saisir announced the maximum price for its H-share issuance at 131.5 HKD per share, with the public offering starting on the same day and expected to end on October 31 [1] - Jinghua Laser plans to invest approximately 200 million yuan in a new project to produce 20,000 tons of UV laser platinum embossed anti-counterfeiting materials [2] Group 2 - Zhenyu Technology intends to invest 2.11 billion yuan in a project for robots and precision structural components, to be developed in three phases from 2025 to 2030 [3] - Qianyuan Power reported a net profit of 493 million yuan for the first three quarters, a year-on-year increase of 85.74%, with total revenue of 2.169 billion yuan, up 47.99% [4] - Haohua Energy's net profit decreased by 50.5% to 554 million yuan, with total revenue of 6.307 billion yuan, down 7.85% [7] Group 3 - Kangtai Biological's net profit fell by 86% to 49.16 million yuan, with total revenue of 2.063 billion yuan, up 2.24% [8] - Huafeng Aluminum reported a net profit of 896 million yuan for the first three quarters, a year-on-year increase of 3.24%, with total revenue of 9.109 billion yuan, up 18.63% [10] - Beiyuan Group's net profit decreased by 10.88% to 214 million yuan, with total revenue of 6.762 billion yuan, down 9.91% [12] Group 4 - Noying Co. reported a net profit of 450 million yuan for the first three quarters, a year-on-year decrease of 22.95%, with total revenue of 31.562 billion yuan, up 2.01% [14] - Chuanhua Zhili's net profit increased by 168.36% to 637 million yuan, despite a revenue decline of 2.74% to 18.84 billion yuan [16] - Jiangsu Sop's net profit decreased by 39.21% to 126 million yuan, with total revenue of 4.661 billion yuan, down 5.74% [18] Group 5 - Yiling Pharmaceutical's net profit increased by 80.33% to 1 billion yuan, with total revenue of 5.868 billion yuan, down 7.82% [20] - Hengwei Technology's net profit decreased by 50.16% to 39.01 million yuan, with total revenue of 739 million yuan, up 16.14% [22] - Gaode Infrared reported a net profit increase of 1058.95% to 582 million yuan, with total revenue of 3.068 billion yuan, up 69.27% [24] Group 6 - Sanxia Water reported a net profit decrease of 8.53% to 351 million yuan, with total revenue of 7.611 billion yuan, down 6.06% [26] - Junda Co. reported a net loss of 419 million yuan for the first three quarters, with total revenue of 5.682 billion yuan, down 30.72% [28] - Shanghai Energy's net profit decreased by 59.22% to 255 million yuan, with total revenue of 5.64 billion yuan, down 22.03% [30] Group 7 - Haizheng Biomaterials reported a net profit decrease of 85.34% to 490,570 yuan, with total revenue of 621 million yuan, down 5.74% [32] - Huisheng Lithium reported a net loss of 103 million yuan, with total revenue of 539 million yuan, up 62.29% [34] - Weicet Technology's net profit increased by 226.41% to 202 million yuan, with total revenue of 1.083 billion yuan, up 46.22% [36] Group 8 - Mengjie Co. reported a net profit increase of 28.69% to 26.52 million yuan, with total revenue of 1.099 billion yuan, down 7.97% [38] - Qingdao Beer terminated its acquisition of 100% equity in Jimo Yellow Wine due to unmet conditions [40] - Sifang Precision plans to issue H-shares and list on the Hong Kong Stock Exchange [42]

Group 1 - Dingjide's subsidiary has successfully launched the industrial production of POE materials, achieving stable production of qualified products [1] - Xinhua Insurance reported a 19% year-on-year increase in original insurance premium income for the first three quarters, totaling 172.705 billion yuan [1] - Chunfeng Power achieved a 30.89% year-on-year increase in net profit for the first three quarters, with total revenue reaching 14.15 billion yuan [1][2] Group 2 - Guangsheng Nonferrous expects a net profit of 100 million to 130 million yuan for the first three quarters, marking a turnaround from losses [1] - Aobi Zhongguang anticipates a net profit of approximately 108 million yuan for the first three quarters, with revenue growth of 103.5% [1] - Guobang Pharmaceutical reported a 15.78% year-on-year increase in net profit for the first three quarters, totaling 6.7 billion yuan [1] Group 3 - Zhujiang Co. manages 428 projects with a signed construction area of approximately 50.9853 million square meters as of September 2025 [1] - Kecuan Technology has terminated its application for issuing convertible bonds, considering its development plan and actual situation [1] - Guoxin Securities has received approval to register 15 billion yuan in short-term corporate bonds [1] Group 4 - Aihua Pharmaceutical's clinical trial for a pediatric cough syrup has been approved by the National Medical Products Administration [1] - Xinjiang Jiaojian signed new construction contracts worth 1.413 billion yuan in the third quarter [1] - Sichuan Shuangma's subsidiary has received approval for the listing of a raw material drug used in treating various diseases [1] Group 5 - Gansu Energy's 1,000 MW coal-fired unit has officially commenced commercial operation [1] - Zhejiang Energy reported a 4.68% year-on-year increase in power generation for the first three quarters, totaling 135.234 billion kWh [1] - Tiandi Source's contract sales amount for the first nine months decreased by 16.18% to 3.085 billion yuan [1] Group 6 - Biological Shares' subsidiary has obtained a new veterinary drug registration certificate for a vaccine [1] - Jintong Co. reported a 4.03% year-on-year increase in net profit for the first three quarters, totaling 2.283 billion yuan [1] - Rihua Technology plans to invest 800 million yuan in a new project for industrial ray detection equipment [1] Group 7 - Zhongtian Technology has won multiple marine project bids totaling approximately 1.788 billion yuan [1] - Qingsong Co. has completed the disposal of a 148-acre industrial park project, transferring it for 163 million yuan [1] - Tongyuan Petroleum has successfully bid for a $126 million oil and gas service project in Algeria [1] Group 8 - Hengmingda's chairman proposed a share buyback plan of 200 million to 400 million yuan [1] - Deyi Cultural plans to reduce its holdings by up to 1% of the company's shares [1] - Feirongda's major shareholder plans to reduce its holdings by up to 2.36% of the company's shares [1] Group 9 - Mankun Technology plans to issue convertible bonds to raise no more than 760 million yuan for high-end PCB production and digital upgrades [1] - Sanlian Forging's shareholder plans to reduce its holdings by up to 3% of the company's shares [1] - Huagong Technology intends to jointly establish a venture capital fund with a target size of 500 million yuan [1] Group 10 - Shida Shenghua expects a net loss of 49 million to 75 million yuan for the first three quarters [1] - Huichuangda's major shareholder plans to reduce its holdings by up to 0.65% of the company's shares [1] - Yuxin Electronics reported a 60.21% year-on-year increase in net profit for the first three quarters, totaling 73.3941 million yuan [1] Group 11 - Yiwei Communication expects a 50% to 55% decline in net profit for the first three quarters [1] - Lio Co. plans to reduce its repurchased shares by up to 135 million shares [1] - Sichuan Shuangma's subsidiary has received approval for a new drug registration [1]